Darzalex Faspro Indications/Uses

Multiple Myeloma: DARZALEX FASPRO is indicated for the treatment of adult patients with multiple myeloma: In combination with lenalidomide and dexamethasone: in patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant; in patients with relapsed or refractory multiple myeloma who have received at least one prior therapy.
In combination with bortezomib, melphalan, and prednisone for the treatment of patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant.
In combination with bortezomib, thalidomide, and dexamethasone in newly diagnosed patients who are eligible for autologous stem cell transplant.
In combination with bortezomib and dexamethasone, for the treatment of patients with multiple myeloma who have received at least one prior therapy.
In combination with pomalidomide and dexamethasone for the treatment of adult patients with multiple myeloma who have received one prior therapy containing a proteasome inhibitor and lenalidomide and were lenalidomide-refractory, or who have received at least two prior therapies that included lenalidomide and a proteasome inhibitor and have demonstrated disease progression on or after the last therapy.
In combination with carfilzomib and dexamethasone in patients with relapsed or refractory multiple myeloma who have received one to three prior lines of therapy.
As monotherapy, for the treatment of patients with multiple myeloma who have received at least three prior lines of therapy including a proteasome inhibitor (PI) and an immunomodulatory agent or who are double-refractory to a PI and an immunomodulatory agent.
Light chain (AL) amyloidosis: DARZALEX FASPRO is indicated in combination with cyclophosphamide, bortezomib, and dexamethasone for the treatment of adult patients with newly diagnosed systemic AL amyloidosis.